-
Product Insights
NewRecessive X Chromosome Disorders – Drugs In Development, 2024
Empower your strategies with our Recessive X Chromosome Disorders – Drugs In Development, 2024 report and make more profitable business decisions. A recessive X chromosome disorder, also known as an X-linked recessive disorder, is a genetic condition caused by a mutation on one of the X chromosomes, one of the two sex chromosomes. Typically, males have one X and one Y chromosome (XY), while females have two X chromosomes (XX). In recessive X-linked disorders, the mutated gene is located on the...
-
Product Insights
NewDuchenne Muscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Duchenne Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. Risk factors include gender and family history. Treatments include steroid medication, respiratory therapy, and surgery. The Duchenne Muscular Dystrophy drugs in development market research report provide comprehensive information...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BIO-101 in Sarcopenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BIO-101 in Sarcopenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BIO-101 in Sarcopenia Drug Details: BIO-101 (SARCONEOS) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GSK-4178116A in Varicella Zoster (HHV-3) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GSK-4178116A in Varicella Zoster (HHV-3) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GSK-4178116A in Varicella Zoster (HHV-3) Infections Drug Details:GSK-4178116A is under development...
-
Company Profile
Biophytis SA – Company Profile
Biophytis SA (Biophytis) is a biotechnology company. The company develops drug candidates to treat age-related degenerative diseases that affects muscular and visual functions. It focuses on therapeutic solutions against age-related, impairing diseases. Biophytis product pipeline include Sarconeos (BIO101), a first-in-class drug candidate for the treatment of sarcopenic obesity and Duchenne muscular dystrophy (DMD) and BIO103 to treat other muscle dystrophies; Macuneos (BIO201) and BIO203 peroxisome proliferator-activated receptors (PPARs) to treat dry age-related macular degeneration (AMD) and other retinal diseases. The...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BIO-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry BIO-101 Drug Details BIO-101 (SARCONEOS) is under development for the treatment of age-related sarcopenia...
-
Product Insights
Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Muscular Dystrophy Pipeline Drugs Market Report Overview Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The report titled ‘Muscular Dystrophy –Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update’, provides an overview of...
-
Product Insights
Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Duchenne Muscular Dystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and...
-
Product Insights
Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Juvenile Macular Degeneration is mostly found in the form of Stargardt disease. Stargardt's disease can occur with symptoms that include blurry or fuzzy vision, dark, empty spots in the center of vision, and difficulty reading or performing detail work. The Juvenile Macular Degeneration (Stargardt Disease) pipeline market research report provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis...
-
Product Insights
Sarcopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Sarcopenia pipeline market research report provides comprehensive information on the therapeutics under development for sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.